Stephen R Johnston

Summary

Affiliation: Royal Marsden Hospital
Country: UK

Publications

  1. ncbi request reprint Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer
    Stephen R D Johnston
    Department of Medicine, Breast Unit, Royal Marsden Hospital NHS Trust, 233 Fulham Road, London SW3 6JJ, United Kingdom
    Clin Cancer Res 12:1061s-1068s. 2006
  2. pmc Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer
    Lee S Schwartzberg
    The West Clinic, Memphis, Tennessee, USA
    Oncologist 15:122-9. 2010
  3. pmc Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer
    A Urruticoechea
    Department of Medicine Breast Unit, Royal Marsden NHS Trust, London and Surrey, England
    Br J Cancer 92:475-9. 2005
  4. pmc Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience
    S Sutherland
    Department of Medicine, The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Fulham Road, Chelsea and Sutton, London, UK
    Br J Cancer 102:995-1002. 2010
  5. ncbi request reprint The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?
    Stephen R D Johnston
    Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, UK
    Curr Oncol Rep 16:358. 2014
  6. doi request reprint Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
    Stephen Rd Johnston
    Royal Marsden NHS Foundation Trust, London, UK
    Lancet Oncol 14:989-98. 2013
  7. doi request reprint The breast cancer genome and the complexity of different subgroups: what does it all mean?
    S R Johnston
    SR Johnston, Department of Medicine The Royal Marsden NHS Foundation Trust Fulham Road, Chelsea London SW3 6JJ, UK
    J R Coll Physicians Edinb 43:36. 2013
  8. doi request reprint A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
    Stephen R D Johnston
    Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Fulham Road, Chelsea, London, UK
    Breast Cancer Res Treat 137:755-66. 2013
  9. pmc BOLERO-2 - will this change practice in advanced breast cancer?
    Stephen Rd Johnston
    The Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, UK
    Breast Cancer Res 14:311. 2012
  10. ncbi request reprint Life following aromatase inhibitors--where now for endocrine sequencing?
    Stephen R Johnston
    Breast Unit, Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK
    Breast Cancer Res Treat 93:S19-25. 2005

Detail Information

Publications51

  1. ncbi request reprint Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer
    Stephen R D Johnston
    Department of Medicine, Breast Unit, Royal Marsden Hospital NHS Trust, 233 Fulham Road, London SW3 6JJ, United Kingdom
    Clin Cancer Res 12:1061s-1068s. 2006
    ..The correlation of molecular and clinical results from these ongoing studies will be important to establish appropriate biological variables for selecting those patients who may benefit most from this combined approach...
  2. pmc Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer
    Lee S Schwartzberg
    The West Clinic, Memphis, Tennessee, USA
    Oncologist 15:122-9. 2010
    ....
  3. pmc Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer
    A Urruticoechea
    Department of Medicine Breast Unit, Royal Marsden NHS Trust, London and Surrey, England
    Br J Cancer 92:475-9. 2005
    ..3). Toxicity profile was mild. This platinum-based chemotherapy is an effective, well-tolerated and low-cost regimen for patients with MBC, including those pretreated with anthracyclines...
  4. pmc Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience
    S Sutherland
    Department of Medicine, The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Fulham Road, Chelsea and Sutton, London, UK
    Br J Cancer 102:995-1002. 2010
    ..The global lapatinib expanded access programme provided access to lapatinib combined with capecitabine for women with HER2-positive metastatic breast cancer (MBC) who previously received anthracycline, taxane and trastuzumab...
  5. ncbi request reprint The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?
    Stephen R D Johnston
    Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, UK
    Curr Oncol Rep 16:358. 2014
    ....
  6. doi request reprint Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
    Stephen Rd Johnston
    Royal Marsden NHS Foundation Trust, London, UK
    Lancet Oncol 14:989-98. 2013
    ..The aim of the SoFEA trial was to assess a maximum double endocrine targeting approach with the steroidal anti-oestrogen fulvestrant in combination with continued oestrogen deprivation...
  7. doi request reprint The breast cancer genome and the complexity of different subgroups: what does it all mean?
    S R Johnston
    SR Johnston, Department of Medicine The Royal Marsden NHS Foundation Trust Fulham Road, Chelsea London SW3 6JJ, UK
    J R Coll Physicians Edinb 43:36. 2013
    ..Curtis C, Shah SP, Chin SF et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346-52...
  8. doi request reprint A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
    Stephen R D Johnston
    Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Fulham Road, Chelsea, London, UK
    Breast Cancer Res Treat 137:755-66. 2013
    ..Toxicity was higher with the combination, including increased diarrhea and liver enzyme elevations...
  9. pmc BOLERO-2 - will this change practice in advanced breast cancer?
    Stephen Rd Johnston
    The Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, UK
    Breast Cancer Res 14:311. 2012
    ..The magnitude of the benefit represents a quantum shift in how we should use endocrine therapy in future, and potentially defines a new standard of care in this setting...
  10. ncbi request reprint Life following aromatase inhibitors--where now for endocrine sequencing?
    Stephen R Johnston
    Breast Unit, Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK
    Breast Cancer Res Treat 93:S19-25. 2005
    ..The steroidal AI, exemestane is also an option in non-steroidal AI-resistant disease. Clinical trials are underway to compare fulvestrant with exemestane as an appropriate therapy following the onset of AI resistance...
  11. ncbi request reprint A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy
    Stephen R D Johnston
    Department of Medicine, Breast Unit, Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, UK
    Breast Cancer Res Treat 110:327-35. 2008
    ..This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast cancer and disease progression following antiestrogen therapy...
  12. ncbi request reprint Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists
    S R D Johnston
    Department of Medicine Breast Unit, Royal Marsden Hospital, London, United Kingdom
    Int J Gynecol Cancer 16:543-8. 2006
    ..Subsequent trials will be needed to see whether combinations of novel STIs are well tolerated and how they may further enhance clinical benefit in breast cancer...
  13. ncbi request reprint Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer
    Stephen R D Johnston
    Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 106:180-6. 2007
    ..This article reviews the rationale for these strategies, and discusses the lessons that need to be learnt if we are to successfully integrate these new drugs with aromatase inhibitors in the clinic...
  14. ncbi request reprint Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer
    Stephen R D Johnston
    Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
    Drugs Today (Barc) 42:441-53. 2006
    ..Parallel biomarker studies are starting to elucidate predictive molecular phenotypes that may indicate likelihood of response to lapatinib, and these may direct future trials with this oral tyrosine kinase inhibitor...
  15. doi request reprint New strategies in estrogen receptor-positive breast cancer
    Stephen R D Johnston
    Department of Medicine, Royal Marsden NHS Foundation Trust, Chelsea, London, United Kingdom
    Clin Cancer Res 16:1979-87. 2010
    ..Enriching trial recruitment by molecular profiling of different ER+ subtypes will become increasingly important to maximize additional benefit that new agents may bring to current endocrine therapies for breast cancer...
  16. doi request reprint Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
    Stephen Johnston
    Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 27:5538-46. 2009
    ....
  17. doi request reprint Enhancing the efficacy of hormonal agents with selected targeted agents
    Stephen R D Johnston
    Department of Medicine, Royal Marsden Hospital, Chelsea, London, UK
    Clin Breast Cancer 9:S28-36. 2009
    ....
  18. pmc Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?
    Stephen R D Johnston
    Department of Medicine Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK
    Breast Cancer Res 7:119-30. 2005
    ..In contrast, SERDs may have useful efficacy following aromatase inhibitors because of their unique mechanism of action, and clinical trials to determine their optimal use or sequence are ongoing...
  19. ncbi request reprint Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance
    Stephen R D Johnston
    Department of Medicine Breast Unit, The Royal Marsden NHS Trust, 233 Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 95:173-81. 2005
    ..This article reviews the pre-clinical rationale for this strategy and the clinical trials in this area...
  20. ncbi request reprint Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
    Thomas Yau
    Breast Unit, Royal Marsden Hospital, Surrey SM2 5PT, UK
    Acta Oncol 45:196-201. 2006
    ..This study shows brain metastases are common phenomenon in HER2 positive advanced breast cancer patients receiving trastuzumab and also may implicate the brain as a sanctuary site for early relapse in this patient cohort...
  21. pmc Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer
    Alexandra F Leary
    Department of Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res 9:112. 2007
    ..This article will review the results of clinical trials of endocrine/biological combinations conducted in early and advanced breast cancer as well as provide an update on ongoing studies...
  22. doi request reprint Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance
    Alexandra F Leary
    Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 16:1486-97. 2010
    ..Changes in ERalpha, PgR, and HER2 were assessed in samples from patients treated with tamoxifen...
  23. ncbi request reprint Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?
    Stephen R D Johnston
    Department of Medicine, Royal Marsden Hospital, Fulham Road, Chelsea, London, UK
    Cancer 112:710-7. 2008
    ....
  24. ncbi request reprint The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo
    Lesley Ann Martin
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, Fulham Road, London, SW3 6JB United Kingdom
    Mol Cancer Ther 6:2458-67. 2007
    ..Enhanced G1 arrest due to modulation of cell cycle regulatory proteins may be the underlying mechanism for the positive interaction between FTIs and tamoxifen...
  25. ncbi request reprint Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation
    Christina M W Chan
    Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 81:333-41. 2002
    ..Thus, the resistance of these human breast cancer cells to oestrogen-deprivation appears to be due to acquired hypersensitivity which may be explained in part by increased levels of and phosphorylated ERalpha...
  26. ncbi request reprint Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation
    Lesley Ann Martin
    Academic Department of Biochemistry, Institute of Cancer Research, London, United Kingdom
    J Biol Chem 278:30458-68. 2003
    ..These data suggest that although elevated levels of MAPK occur during LTED and influence the phenotype, this is unlikely to be the sole pathway operating to achieve adaptation...
  27. ncbi request reprint Aromatase inhibitors for breast cancer: lessons from the laboratory
    Stephen R D Johnston
    Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    Nat Rev Cancer 3:821-31. 2003
  28. ncbi request reprint Novel systemic therapies for breast cancer
    Soo Lo
    Department of Medicine Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Surg Oncol 12:277-87. 2003
    ..As these new therapies evolve towards the clinic, the challenge to oncologists is whether their potential seen in the laboratory can be matched by further substantial improvements in clinical outcome...
  29. ncbi request reprint Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer
    Stephen R D Johnston
    Departments of Medicine and Academic Biochemistry, Royal Marsden Hospital and Institute of Cancer Research, London SW3 6JJ, United Kingdom
    Clin Cancer Res 9:524S-32S. 2003
    ....
  30. ncbi request reprint Fulvestrant (AstraZeneca)
    Stephen R D Johnston
    Department of Medicine, Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Curr Opin Investig Drugs 3:305-12. 2002
    ..Analysts at Lehman Brothers predicted in December 2001, that the product has a 90% chance of making it to market in 2002, with peak sales potential in this year of $800 million [434768]...
  31. doi request reprint Ipsilateral breast tumor recurrence: is there any evidence for benefit of further systemic therapy?
    Bhawna Sirohi
    Breast Unit, Royal Marsden NHS Foundation Trust, Surrey, UK
    Breast J 15:268-78. 2009
    ..Regional nodal recurrence including supraclavicular node recurrence is not dealt with in this review...
  32. pmc New targets for therapy in breast cancer: farnesyltransferase inhibitors
    Julia Head
    Department of Medicine, Royal Marsden Hospital, London, UK
    Breast Cancer Res 6:262-8. 2004
    ....
  33. ncbi request reprint Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer
    Stephen R D Johnston
    Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    J Clin Oncol 21:2492-9. 2003
    ..We conducted a phase II study in 76 patients with advanced breast cancer...
  34. ncbi request reprint Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model
    Simone Detre
    Academic Department of Biochemistry, The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, U K
    Cancer Res 63:6516-22. 2003
    ..These results show that ARZ is an effective antagonist of E2-stimulated breast cancer growth with similar growth-inhibitory and pharmacodynamic effects to TAM in this model...
  35. ncbi request reprint Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations
    Stephen R D Johnston
    Department of Medicine Breast Unit, Royal Marsden Hospital, London, UK
    Cancer Invest 22:730-42. 2004
    ..Accounting for all available data, NICE guidance supports the appropriate roles of paclitaxel, topotecan, and pegylated liposomal doxorubicin in the treatment of advanced ovarian cancer...
  36. ncbi request reprint BMS-214662 (Bristol-Myers Squibb)
    Stephen R D Johnston
    Department of Medicine Breast Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    IDrugs 6:72-8. 2003
    ..By October 2000, preclinical investigations were ongoing in Japan. By February 2001, the drug was in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers...
  37. ncbi request reprint A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer
    Hugo E R Ford
    Department of Medicine, Breast Unit, Royal Marsden NHS Trust, 233 Fulham Road, SW3 6JJ, London, United Kingdom
    Cancer Chemother Pharmacol 58:809-15. 2006
    ..We evaluated the toxicity and the activity of weekly docetaxel in anthracycline-pretreated patients...
  38. ncbi request reprint Small molecule signal transduction inhibitors for the treatment of solid tumors
    Alexandra Leary
    The Royal Marsden Hospital, London, UK
    Cancer Invest 25:347-65. 2007
    ..This review will discuss the small molecule signal transduction inhibitors in various stages of development and address the strategic issues relating to clinical trial design with these novel targeted agents...
  39. ncbi request reprint Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 9:443S-6S. 2003
  40. ncbi request reprint Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Pharmacoeconomics 24:237-50. 2006
    ..The objective of this evaluation was to extrapolate the findings from the MA17 trial to estimate the lifetime cost effectiveness of letrozole in this setting...
  41. ncbi request reprint Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation
    Lesley Ann Martin
    Molecular Endocrinology, Breakthrough Breast Cancer Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Rd, London SW3 6JB, UK
    Endocr Relat Cancer 12:S75-84. 2005
    ....
  42. ncbi request reprint Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference
    Steven E Come
    Breast Cancer Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 112:673-8. 2008
    ..All of this has and continues to contribute to a growing understanding of how to optimize the use of endocrine agents in both treating and preventing breast cancer...
  43. ncbi request reprint Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer
    Thomas E Delea
    Policy Analysis Inc, 4 Davis Court, Brookline, MA 02245, USA
    Am J Manag Care 12:374-86. 2006
    ..To estimate the cost-effectiveness of extended adjuvant letrozole in postmenopausal women with early breast cancer and estrogen or progesterone receptor-positive tumors who had completed 5 years of adjuvant tamoxifen...
  44. ncbi request reprint The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer
    Sacha J Howell
    CRC Department of Medical Oncology, University of Manchester, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK
    Best Pract Res Clin Endocrinol Metab 18:47-66. 2004
    ..029). Future clinical studies will evaluate fulvestrant in the neoadjuvant setting together with its optimal sequencing in relation to tamoxifen and other endocrine therapies in advanced disease...
  45. ncbi request reprint Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement
    Steven E Come
    Breast Cancer Program, Beth Israel Deaconess Medical Center Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 12:997s-1000s. 2006
  46. ncbi request reprint Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 11:861s-4s. 2005
  47. ncbi request reprint Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex
    Bin Chen
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Int J Oncol 27:327-35. 2005
    ..We conclude that endogenous ERbeta may not play a dominant role in the modulation of the tamoxifen ERalpha complex, or in the development of tamoxifen-stimulated resistant tumor growth...